Recent Analysts’ Ratings Updates for Collegium Pharmaceutical (COLL)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for Collegium Pharmaceutical (NASDAQ: COLL):

  • 10/11/2019 – Collegium Pharmaceutical was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
  • 10/11/2019 – Collegium Pharmaceutical was given a new $33.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 10/10/2019 – Collegium Pharmaceutical was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
  • 9/27/2019 – Collegium Pharmaceutical was given a new $33.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 9/17/2019 – Collegium Pharmaceutical had its “buy” rating reaffirmed by analysts at William Blair.

Shares of Collegium Pharmaceutical stock traded up $0.26 on Tuesday, hitting $12.05. The company had a trading volume of 41,475 shares, compared to its average volume of 302,851. The stock has a market capitalization of $394.62 million, a price-to-earnings ratio of -10.13 and a beta of 0.52. Collegium Pharmaceutical Inc has a 1 year low of $10.01 and a 1 year high of $19.83. The stock has a 50 day moving average of $11.49 and a 200-day moving average of $12.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.20 and a current ratio of 1.25.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm had revenue of $75.04 million during the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.40) earnings per share. Equities analysts anticipate that Collegium Pharmaceutical Inc will post -0.39 earnings per share for the current year.

In other news, Director David Hirsch sold 22,106 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the completion of the sale, the director now directly owns 64,223 shares of the company’s stock, valued at $748,197.95. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 8.08% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 19.1% during the second quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after acquiring an additional 693,812 shares during the last quarter. BlackRock Inc. increased its position in shares of Collegium Pharmaceutical by 7.1% during the second quarter. BlackRock Inc. now owns 2,488,479 shares of the specialty pharmaceutical company’s stock valued at $32,724,000 after acquiring an additional 165,018 shares during the last quarter. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 1.5% during the second quarter. Vanguard Group Inc. now owns 1,571,474 shares of the specialty pharmaceutical company’s stock valued at $20,665,000 after purchasing an additional 22,883 shares during the period. Rice Hall James & Associates LLC grew its holdings in Collegium Pharmaceutical by 5.8% during the second quarter. Rice Hall James & Associates LLC now owns 1,260,690 shares of the specialty pharmaceutical company’s stock valued at $16,578,000 after purchasing an additional 69,549 shares during the period. Finally, Cortina Asset Management LLC grew its holdings in Collegium Pharmaceutical by 81.0% during the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock valued at $6,703,000 after purchasing an additional 228,035 shares during the period. 92.08% of the stock is owned by institutional investors.

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: What is total return in investing?

Receive News & Ratings for Collegium Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.